A health worker administers a third dose of the Pfizer-BioNTech Covid-19 vaccine at a nursing home in Worcester, Pennsylvania, USA, on Wednesday, August 25, 2021.
Hannah Beier | Bloomberg | Getty Images
The side effects of Covid booster doses are similar to those felt after the second dose and are more likely to affect younger people, according to Pfizer, in new data presented to the Food and Drug Administration, while seeks approval to distribute booster outlets in the United States.
The Pfizer Phase 3 study on booster doses, which included a group of about 300 participants aged 18 to 55, found that 63.7% experienced fatigue after getting their booster, 48 , 4% had a headache and 39.1% felt muscle pain. Most reactions to the reinforcement were mild to moderate in severity, the company said in a 52-page report released by the agency on Wednesday. The company, along with BioNTech, are seeking FDA emergency approval to administer third-dose doses to people 16 years of age or older throughout the U.S.
Pfizer previously assessed side effects in 2,682 second-dose recipients aged 16 to 55 years and found that 61.5% developed fatigue, 54% suffered from headaches and 39.3% treated muscle pain.
The study also tracked adverse events among 306 booster receptors, 44 of which developed at least one unexpected side effect. The most common adverse event, inflammation of the lymph nodes, occurred in 16 of the participants.